Month: September 2023

CINCINNATI, Sept. 26, 2023 (GLOBE NEWSWIRE) — Phillips Edison & Company, Inc. (Nasdaq: PECO) (“PECO), one of the nation’s largest owners and operators of grocery-anchored neighborhood shopping centers, will announce its Third Quarter 2023 earnings results on Tuesday, October 31, 2023, after the market closes. PECO’s earnings release and supplemental information package will be posted on the Investor Relations section of the Company’s website at https://investors.phillipsedison.com/. Chairman and Chief Executive Officer Jeff Edison, President Devin Murphy, and Chief Financial Officer John Caulfield will host an earnings conference call, which will also be webcast, on Wednesday, November 1, 2023, at 12:00 p.m. ET. Third Quarter 2023 Earnings Conference Call Details:Date: Wednesday, November 1, 2023 Time: 12:00 p.m. ET Toll-Free...

Highlights:The ECOLOGO® certification process incorporated over one hundred criteria, encompassing practices on environment, health and safety, governance, community relations, Indigenous relations, innovation, and contribution to local economy. As part of this certification, Probe Gold met all the responsible development indicators including:Respect for the principles of sustainable development in the value chain Environmental quality (efficient use of resources, air quality, soil quality, respect for sensitive areas and wildlife habitat) Quality of life (recognition of the concerns and accommodation of local and indigenous communities, quality of the visual environment, health and safety of populations, respect for cultural heritage)         Local investment (selection of local labour, selection of local suppliers) Work environment...

WASHINGTON, Sept. 26, 2023 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointments of Cynthia Romano and Chris Creger as Senior Managing Directors in the Turnaround & Restructuring practice within the firm’s Corporate Finance & Restructuring segment. “Cynthia and Chris have a track record of helping clients get back to the basics of growing revenue, cutting unnecessary expenses and improving operations,” said Michael Eisenband, Global Co-Leader of the Corporate Finance & Restructuring segment at FTI Consulting. “Their restructuring leadership and performance improvement expertise combined with our deep bench of industry experts will help our clients transform their bottom line to maximize value for owners, investors and other stakeholders.” Ms. Romano, who splits her time between New...

BEIJING, Sept. 26, 2023 (GLOBE NEWSWIRE) — Fang Holdings Limited (OTC: SFUNY) (“Fang” or the “Company”), a leading real estate Internet portal in China, today announced that its board of directors (the “Board”) has formed a special committee (the “Special Committee”) consisting of three independent directors, Mr. Huyue Zhang, Mr. Shaohua Zhang and Mr. Changming Yan, to evaluate and consider the previously announced preliminary non-binding acquisition proposal letter dated September 4, 2023 (the “Proposal”) from Mr. Jiangong Dai (“Mr. Dai” or the “Proposing Buyer”) to acquire all of the outstanding shares of the Company not currently owned by the Proposing Buyer, or any potential alternative transactions. The Board cautions the Company’s shareholders and others considering trading the Company’s securities that no decisions have...

WINTER PARK, Fla., Sept. 26, 2023 (GLOBE NEWSWIRE) — CTO Realty Growth (NYSE: CTO) (the “Company”) announced today that it will report its financial and operating results for the third quarter of 2023 after the market closes on Thursday, October 26, 2023. A conference call to discuss its financial and operating results is scheduled for Friday, October 27, 2023 at 9:00 AM ET. A live webcast of the call will be available on the Investor Relations page of the Company’s website at www.ctoreit.com or at the link provided in the event details below. To access the call by phone, please go to the registration link provided in the event details below and you will be provided with dial-in details. Event Details:Webcast: https://edge.media-server.com/mmc/p/zzoarkysRegistration: https://register.vevent.com/register/BIc2862b1fbbca4c92b7d5c569a5f682e5   We...

Marina Golubeva and Ali Rakib join the company as the Digital Trade and Supply Chain Finance provider expands its lending portfolio in both emerging and developed markets DUBAI, United Arab Emirates, Sept. 26, 2023 (GLOBE NEWSWIRE) — Triterras, Inc. (“Triterras” or the “Company”) a leading fintech company focused on trade and trade finance, announces the hiring of two new members to the Distribution team. Marina Golubeva and Ali Rakib will engage with institutional investors who are interested in deploying capital for cross-border trade finance opportunities. Marina and Ali will report to Marina Naganes, Head of Distribution & Sales Strategy. Ms. Golubeva joins the Distribution team as Vice President of Business Development. Prior to Triterras, Ms. Golubeva worked in trade and structured finance for BTA Bank, Nordea Bank and...

GAITHERSBURG, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Louis J. Aronne, Founder and Director of the Center for Weight Management at Weill-Cornell Medical Center, and a leading authority in obesity, will present the results of its 24-week clinical trial of pemvidutide in the treatment of subjects with overweight or obesity in an oral presentation at the 59th Annual Meeting of the European Association for the Study of Diabetes in Hamburg, Germany. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and non-alcoholic steatohepatitis (NASH). Details for the oral presentation are as follows:Title: Phase 2, Randomized, Placebo-controlled Trial of pemvidutide,...

Not for Distribution to United States Newswire Services or for Dissemination in the United States VANCOUVER, British Columbia, Sept. 26, 2023 (GLOBE NEWSWIRE) — Deep-South Resources Inc. (“Deep-South” or the Company) (TSX-V: DSM) announces that the Company closed the second tranche of its oversubscribed non-brokered private placement (“Private Placement”) for an amount totaling $1,803,282. The first tranche closed September 6, 2023 for an amount of $265,447. The two tranches together total $2,068,729. In aggregate, the two tranches of the Private Placement comprise 31,826,596 units (the “Units”) of Deep-South, at a subscription price of $0.065 per Unit. Each Unit consists of one (1) common share and one half (1/2) of one common share purchase warrant (“Warrant”). Each full Warrant will entitle the holder thereof to...

Efficacy ChartEfficacy results in both cohorts at baseline and at Week 4 following the dose of SPL026 with support therapy• Results suggest that SSRIs enhance the efficacy of SPL026 (DMT) when administered to MDD patients on a stable dose of SSRIs versus patients not on SSRIs • At Week 4, 100% of patients in the SSRI cohort responded to SPL026 (DMT) with 92% of patients in remission from depression • No apparent differences in the safety and tolerability profile of SPL026 (DMT) following administration to participants in the SSRI and non-SSRI patient cohorts LONDON, Sept. 26, 2023 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces positive safety,...

NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that it will host a Research & Development (R&D) Day investor event on Monday, October 2, 2023. The event will take place at the Company’s headquarters in New York’s Hudson Yards from 12:00 pm – 2:30 pm and will be webcast simultaneously. Ovid management will provide updates on Ovid’s scientific strategy and anticipated clinical development plans. Additionally, the Company’s research and development leadership will review new data characterizing how the unique mechanisms of action in its pipeline address the underlying causes of neuronal hyperexcitability and may hold broader...